Vir Biotechnology (VIR) Stock Forecast: StockMap's 2-Week Call
VIR stock forecast: StockMap's model makes no two-week call on Vir Biotechnology after the Nov 13 close: its evidence is split, 2 reasons for and 13 against. Too few two-week windows graded to judge yet.
Vir Biotechnology last closed at $9.96, -17.82% on the session.
Against the IVW growth benchmark the position is -16.91% over the forecast window.
Vir Biotechnology's market cap is $1.71B as of November 13, 2026.
No call today: the model sees no clear direction · the next 2 weeks, vs S&P 500 growth. The lean on a scale from −100 to +100 is -6 (too close to call).
Where VIR sits: sized by market cap, coloured by the day's move.
The read is built from 15 underlying insights — 2 bullish and 13 bearish.
Agreement across those insights is 87%.
3 daily calls for VIR so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.
On the fundamentals StockMap ranks Vir Biotechnology in the 27th percentile on return on equity, where 100 is best.
Vir Biotechnology is classified under Health Care / Biotechnology.
StockMap tracks Vir Biotechnology as the 100th largest of the 391 companies it covers in the Biotechnology industry, part of the Health Care sector.
Across that group the current two-week reads are 186 Moderate Underperform, 157 Neutral, 33 Strong Underperform and 15 Moderate Outperform.
On that composite Vir Biotechnology ranks 105th of 391 in the group, against a group median of -0.24.